SynthesisFrontiers in oncology2026
Postoperative ctDNA could potentially spare patients from unnecessary adjuvant therapy in HPV-negative head and neck squamous cell carcinoma: a meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic utility of circulating tumor DNA (ctDNA) for minimal residual disease detection in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) remains incompletely characterized. This meta-analysis evaluates the association between post-operative ctDNA and recurrence-free survival (RFS) in this population. Methods: A systematic search of major databases through May 2026 identified studies evaluating post-operative ctDNA and RFS in HPV-negative HNSCC. Pooled hazard ratios (HRs) were calculated using a random-effects model. Results: Eight studies (n=325) were included. Detectable post-operative ctDNA was associated with diminished RFS (HR = 10.07, 95% CI: 5.64-17.99) and overall survival (HR = 8.98, 95% CI: 2.93-27.58). However, sensitivity analyses substantially attenuated the pooled RFS estimate (HR range: 2.22-2.43), suggesting the primary effect magnitude may lack stability. Conclusions: While preliminary evidence suggests an association between post-operative ctDNA and recurrence risk in HPV-negative HNSCC, these findings require cautious interpretation. The current literature is constrained by small sample sizes, heterogeneous detection methodologies, mixed-cohort inclusion, and potential confounding biases. Consequently, post-operative ctDNA remains an investigational biomarker in this setting. Clinical implementation necessitates further validation through large, prospective, multi-institutional studies employing standardized methodologies in strictly defined HPV-negative #146;populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.